EPIZYME INC (EPZM)

Company Profile

Epizyme, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 250 full-time employees. The company went IPO on 2013-05-31. The firm is engaged in the treatment of people with cancer through the discovery, development, and commercialization of epigenetic medicines. The firm's lead product TAZVERIK (tazemetostat) is used for epithelioid sarcoma (ES), and follicular lymphoma (FL). Tazemetostat is an oral, selective small molecule inhibitor of the EZH2 histone methyltransferase (HMT), for the treatment of adult and pediatric patients aged 16 years and older with metastatic or locally advanced ES not eligible for complete resection. The company is developing tazemetostat for lymphomas and B-cell malignancies, including B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), multiple myeloma and others. Its advanced product candidate, EZM0414, is an oral inhibitor of the SETD2 HMT. The firm is assessing the use of tazemetostat for immuno-oncology-sensitive tumors, such as small cell lung cancer, prostate cancer, and others.

Company Info

EPIZYME INC

400 Technology Sq Ste 4

Cambridge MASSACHUSETTS 02139

P: 16172295872.0

CEO: Robert B. Bazemore

Employees: 250

Website: http://www.epizyme.com/